dr. (Ken) WK Redekop

Associate professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)

Location: Burg. Oudlaan 50, Rotterdam
Room: J8-29
Email: redekop@eshpm.eur.nl

More information

Profile

Ken Redekop, Ph.D. is an associate professor at the Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, The Netherlands. He is a clinical epidemiologist with more than 20 years of experience in observational research, clinical trial analysis, and medical technology assessment and an author of over 100 papers in the medical literature. Current studies include early-stage cost-effectiveness analyses of medical devices and tests, RCT-based economic evaluations, economic evaluations in the Diagnostics Assessment programme of the National Institute for Health and Clinical Excellence (NICE, UK) and outcomes research studies to determine the effectiveness and cost-effectiveness of expensive medicines in daily practice. Most studies relate to diabetes, cardiovascular disease, and cancer, and most involve modelling and evidence synthesis.

Donald RJ Singer, WK (Ken) Redekop & Bernard Cheung (2020) - Trusted writing in social media - Health Policy and Technology, 9 (1), 5-6 - doi: 10.1016/j.hlpt.2020.02.004
DRJ Singer & Ken Redekop (2020) - What is ahead for health policy and technology in the 2020s? - Health Policy and Technology, 9 (1), 3-4 - doi: 10.1016/j.hlpt.2020.02.003
Laurenske Visser, C Louapre, Carin Groot & Ken Redekop (2020) - Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review - Multiple Sclerosis and Related Disorders, 39, 101929 - doi: 10.1016/j.msard.2020.101929
Anne-Claire Peultier, D Venetsanos, I Rashid, Hans Severens & Ken Redekop (2020) - European survey on acute coronary syndrome diagnosis and revascularisation treatment: Assessing differences in reported clinical practice with a focus on strategies for specific patient cases - Journal of Evaluation in Clinical Practice, 26 (5), 1457-1466 - doi: 10.1111/jep.13333
K Kolasa, Ken Redekop, A Berler, V Zah & CV Asche (2020) - Future of data analytics in the era of the General Data Protection Regulation in Europe - Pharmacoeconomics (Print), 38 (10), 1021-1029 - doi: 10.1007/s40273-020-00927-1
Lytske Bakker, K Vaporidi, Jos Aarts & Ken Redekop (2020) - The potential of real-time analytics to improve care for mechanically ventilated patients in the intensive care unit: an early economic evaluation - Cost Effectiveness and Resource Allocation - doi: 10.1186/s12962-020-00254-4
Lytske Bakker, Jos Aarts, Carin Groot & Ken Redekop (2020) - Economic evaluations of big data analytics for clinical decision-making: a scoping review - Journal of the American Medical Informatics Association - doi: 10.1093/jamia/ocaa102
Anne-Claire Peultier, A Pandya, R Sharma, Hans Severens & Ken Redekop (2020) - Cost-effectiveness of Mechanical Thrombectomy More Than 6 Hours After Symptom Onset Among Patients With Acute Ischemic Stroke - JAMA network open, 3 (8) - doi: 10.1001/jamanetworkopen.2020.12476
Edeltraud Lenk, HC Moungui, M Boussinesq, J Kamgno, HC Nana-Djeunga, C Fitzpatrick, Anne-Claire Peultier, AD Klion, DA Fletcher, TB Nutman, SD Pion, Y Niamsi-Emalio, Ken Redekop, Hans Severens & Wilma Stolk (2020) - A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa-coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon - Clinical Infectious Diseases, 70 (8), 1628-1635 - doi: 10.1093/cid/ciz461
Anne-Claire Peultier, Ken Redekop, M Allen, J Peters, O F Eker & Hans Severens (2019) - Exploring the Cost-Effectiveness of Mechanical Thrombectomy Beyond 6 Hours Following Advanced Imaging in the United Kingdom - Stroke, 50 (11), 3220-3227 - doi: 10.1161/strokeaha.119.026816
Anne-Claire Peultier, Ken Redekop, Diederik Dippel, D Bereczki, S Si-Mohamed, PC Douek & Hans Severens (2019) - What stroke image do we want? European survey on acute stroke imaging and revascularisation treatment - Health Policy and Technology, 8 (33), 261-267 - doi: 10.1016/j.hlpt.2019.08.005
Leander Buisman, AJ Rijnsburger, Aad Lugt, PJ Nederkoorn, Peter Koudstaal & Ken Redekop (2019) - Cost-effectiveness of novel imaging tests to select patients for carotid endarterectomy - Health Policy and Technology, 8 (2), 111-117 - doi: 10.1016/j.hlpt.2019.05.001 - [link]
Ken Redekop (2018) - Fake news, big data, and the opportunities and threats of targeted actions - Health Policy and Technology, 7 (2), 113-114 - doi: 10.1016/j.hlpt.2018.05.001 - [link]
Edeltraud Lenk, Ken Redekop, Marianne Luyendijk, C Fitzpatrick, L Niessen, Wilma Stolk, F Tediosi, AJ Rijnsburger, Roel Bakker, Jan Hontelez, Jan hendrik Richardus, J Jacobson, Epke Rütte, Sake Vlas & Hans Severens (2018) - Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease - PLoS Neglected Tropical Diseases (online), 12 (3) - doi: 10.1371/journal.pntd.0006250
Anne-Claire Peultier, Ken Redekop, E Coche & Hans Severens (2018) - What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries - Expert review of pharmacoeconomics & outcomes research, Volume 18 (2) - doi: 10.1080/14737167.2018.1429270
S Nestler-Parr, D Korchagina, M Toumi, CL Pashos, C Blanchette, E Molsen, T Morel, S Simoens, Z Kalo, R Gatermann & Ken Redekop (2018) - Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. - Value in Health, 21 (5), 493-500 - doi: 10.1016/j.jval.2018.03.004 - [link]
Ken Redekop, Lytske Bakker & Jos Aarts (2018) - Healthcare problems cannot be solved using health technologies alone: The example of precision medicine - Health Policy and Technology, 7 (1), 3-4 - doi: 10.1016/j.hlpt.2018.01.006 - [link]
Amir Ansaripour, K Zendehdel, N Tadayon, F Sadeghi, Carin Groot & Ken Redekop (2018) - Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran - PLoS One (online), 13 (10) - doi: 10.1371/journal.pone.0205079
Amir Ansaripour, Carin Groot & Ken Redekop (2018) - Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"' - Pharmacoeconomics (Print), 36 (3), 381-382 - doi: 10.1007/s40273-018-0620-y
Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
F Paolucci, Ken Redekop, A Fouda & G Fiorentini (2017) - Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage - Applied Health Economics and Health Policy, 15 (6), 697-706 - doi: 10.1007/s40258-017-0349-3
Tim Kanters, Ken Redekop & Leona Roijen (2017) - International differences in patient access to ultra-orphan drugs - Health Policy and Technology, 7, 57-64 - doi: 10.1016/j.hlpt.2017.12.001
Amir Ansaripour, Bing Thio, R Maessen & Ken Redekop (2017) - The cost–effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis - Journal of Comparative Effectiveness Research - doi: 10.2217/cer-2017-0007
Tim Kanters, Ans Ploeg, Michelle Kruijshaar, Dimitris Rizopoulos, Ken Redekop, Maureen Molken & Leona Roijen (2017) - Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease - Orphanet Journal of Rare Diseases, 12 - doi: 10.1186/s13023-017-0731-0 - [link]
Ken Redekop (2017) - Mapping the dimensions of Health Policy and Technology - Health Policy and Technology, 6 (2), 121-123 - doi: 10.1016/j.hlpt.2017.05.001 - [link]
Ken Redekop, Edeltraud Lenk, Marianne Luyendijk, C Fitzpatrick, L Niessen, Wilma Stolk, F Tediosi, AJ Rijnsburger, Roel Bakker, Jan Hontelez, Jan hendrik Richardus, J Jacobson, Sake Vlas & Hans Severens (2017) - The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases - PLoS Neglected Tropical Diseases (online), 11 (1) - doi: 10.1371/journal.pntd.0005289
CA van Bochove, LT (Laura) Burgers, AC Vahl, Erwin Birnie, MG van Schothorst & Ken Redekop (2016) - Cost-effectiveness of open versus endovascular repair of abdominal aortic aneurysm - Journal of Vascular Surgery, 63 (3), 827-838 - doi: 10.1016/j.jvs.2015.10.055
Amir Ansaripour, Carin Groot, M Foroozanfar, S Rahimimoghadam & Ken Redekop (2016) - Which is more important for doctors in a middle-income country, a national guideline or the medical literature? An adherence survey of trastuzumab use for breast cancer in Iran - Journal of Cancer Policy, 9, 8-13 - doi: 10.1016/j.jcpo.2016.05.005
LT (Laura) Burgers, EA McClellan, IE Hoefer, G Pasterkamp, JW Jukema, S (Sebastiaan) Horsman, NHJ Pijls, J Waltenberger, M Hillaert, A Stubbs, Hans Severens & Ken Redekop (2016) - Treatment variation in stent choice in patients with stable or unstable coronary artery disease - Netherlands Heart Journal, 24, 110-119 - doi: 10.1007/s12471-015-0783-5
Edeltraud Lenk, Ken Redekop, Marianne Luyendijk, AJ Rijnsburger & Hans Severens (2016) - Productivity Loss Related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review - PLoS Neglected Tropical Diseases (print), 10 (2), 1-19 - doi: 10.1371/journal.pntd.0004397
Leander Buisman, Maureen Molken, D Postmus, JJ Luime, Carin Groot & Ken Redekop (2016) - The early bird catches the worm: early cost-effectiveness analysis of new medical tests - International Journal of Technology Assessment in Health Care, 32 (1-2), 46-53 - doi: 10.1017/S0266462316000064
LT (Laura) Burgers, AC Vahl, Hans Severens, AM Wiersema, PWM Cuypers, Hence Verhagen & Ken Redekop (2016) - Cost-effectiveness of Elective Endovascular Aneurysm Repair Versus Open Surgical Repair of Abdominal Aortic Aneurysms - European Journal of Vascular and Endovascular Surgery, 52 (1), 29-40 - doi: 10.1016/j.ejvs.2016.03.001
Sake Vlas, Wilma Stolk, Epke Rütte, Jan Hontelez, Roel Bakker, David Blok, Cherry Cai, Tanja Houweling, Margarete Kulik, Edeltraud Lenk, Marianne Luyendijk, Suzette Matthijsse, Ken Redekop, Inge Wagenaar, J Jacobson, Nico Nagelkerke & Jan hendrik Richardus (2016) - Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained? - PLoS Neglected Tropical Diseases (print), 10 (2) - doi: 10.1371/journal.pntd.0004386
Saskia Groot, Stefan Sleijfer, Ken Redekop, E Oosterwijk, JB Haanen, LALM Kiemeney & Carin Groot (2016) - Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry - BMC Cancer, 16, 364 - doi: 10.1186/s12885-016-2395-x
Saskia Groot, Ken Redekop, Stefan Sleijfer, E Oosterwijk, A Bex, LALM Kiemeney & Carin Groot (2016) - Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry - Urology, 95, 121-127 - doi: 10.1016/j.urology.2016.04.042
Rohit Oemrawsingh, Martijn Akkerhuis, Laura Vark, Ken Redekop, Goran Rudez, WJ Remme, ME Bertrand, KM Fox, R Ferrari, Jan Danser, Moniek Maat, Maarten Simoons, Jasper Brugts & Eric Boersma (2016) - Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model - Journal of the American Heart Association, 5 (3), e002688 - doi: 10.1161/JAHA.115.002688
LT (Laura) Burgers, Ken Redekop, Maiwenn Al, SK (Stefan) Lhachimi, N Armstrong, S Walker, C Rothery, M Westwood & Hans Severens (2016) - Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients - European Journal of Health Economics (HEPAC), 1-12 - doi: 10.1007/s10198-016-0824-z
NT Rosendaal, ME Hendriks, MD Verhagen, OA Bolarinwa, EO Sanya, PM Kolo, P Adenusi, K Agbede, D van Eck, Siok Swan Tan, TM Akande, Ken Redekop, C Schultsz & GB Gomez (2016) - Costs and Cost-Effectiveness of Hypertension Screening and Treatment in Adults with Hypertension in Rural Nigeria in the Context of a Health Insurance Program - PLoS One (print), 11 (6), e0157925 - doi: 10.1371/journal.pone.0157925
TI Verhoef, Ken Redekop, S Langenskiold, F Kamali, M Wadelius, G Burnside, AH Maitland-van der Zee, DA Hughes & M Pirmohamed (2016) - Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden - Pharmacogenomics Journal, 16 (5), 478-484 - doi: 10.1038/tpj.2016.41
B Wijnen, G van Mastrigt, Ken Redekop, H Majoie, R de Kinderen & Stefanie Evers (2016) - How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3) - Expert review of pharmacoeconomics & outcomes research, 16 (6), 723-732 - doi: 10.1080/14737167.2016.1246961
Annemieke Leunis, Ken Redekop & Carin Groot (2016) - Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. - Value in Health, 19 (6), 834-843 - doi: 10.1016/j.jval.2016.05.008
Leander Buisman, AJ Rijnsburger, HM den Hertog, Aad Lugt & Ken Redekop (2016) - Clinical Practice Variation Needs to be Considered in Cost-Effectiveness Analyses: A Case Study of Patients with a Recent Transient Ischemic Attack or Minor Ischemic Stroke - Applied Health Economics and Health Policy, 14 (1), 67-75 - doi: 10.1007/s40258-015-0167-4
LT (Laura) Burgers, FT van de Wetering, Hans Severens & Ken Redekop (2016) - Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study - BMC Health Services Research, 16 (23) - doi: 10.1186/s12913-015-1230-4
HJ Fugel, M Nuijten, M Postma & Ken Redekop (2016) - Economic evaluation in stratified medicine: methodological issues and challenges - Frontiers in Pharmacology, 7 - doi: 10.3389/fphar.2016.00113
Tim Kanters, Ken Redekop, Maureen Molken, Michelle Kruijshaar, Deniz Gungor, Ans Ploeg & Leona Roijen (2015) - A conceptual disease model for adult Pompe disease - Orphanet Journal of Rare Diseases, 10 - doi: 10.1186/s13023-015-0334-6
Lucas Goossens, Ken Redekop & Chantal Gils (2015) - Noncollapsibility and Censoring: What's the Bias in Estimating Effects on Survival? - Epidemiology, 26 (1), e1-e2 - doi: 10.1097/EDE.0000000000000197
Tim Kanters, Ken Redekop, Michelle Kruijshaar, Ans Ploeg, Maureen Molken & Leona Roijen (2015) - Comparison of EQ-5D and SF-6D utilities in Pompe disease - Quality of Life Research, 24, 837-844 - doi: 10.1007/s11136-014-0833-2
Tim Kanters, Leona Roijen, Maureen Molken & Ken Redekop (2015) - Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug? - Expert review of pharmacoeconomics & outcomes research, 15 (4), 557-559 - doi: 10.1586/14737167.2015.1045882
Leander Buisman, Siok Swan Tan, PJ Nederkoorn, Peter Koudstaal & Ken Redekop (2015) - Hospital costs of ischemic stroke and TIA in the Netherlands - Neurology, 84 (22), 2208-2215 - doi: 10.1212/WNL.0000000000001635
KM (Kim Marleine) Holtzer - Goor, JG (Jennifer G.) Gaultney, P van Houten, AS Wagg, Simone Huygens, MM Nielen, CP Albers-Heitner, Ken Redekop, Maureen Molken & Maiwenn Al (2015) - Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. - PLoS One (print), 10 (10) - doi: 10.1371/journal.pone.0138225
JG (Jennifer G.) Gaultney, Margreet Franken, Carin Groot, Ken Redekop, PC Huijgens, Ronnie Holt, HM Lokhorst & Pieter Sonneveld (2015) - Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement - Health Policy, 119 (2), 186-194 - doi: 10.1016/j.healthpol.2014.11.010
Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
ME Hendriks, OA Bolarinwa, H Nelissen, AC Boers, GB Gomez, Siok Swan Tan, Ken Redekop, P Adenusi, JMA Lange, K Agbede, TM Akande & C Schultsz (2015) - Costs of cardiovascular disease prevention care and scenarios for cost saving: a micro-costing study from rural Nigeria. - Journal of Hypertension, 33 (2), 376-684 - doi: 10.1097/HJH.0000000000000402
TI Verhoef, Ken Redekop, F Hasrat, A de Boer & AH Maitland-van der Zee (2014) - Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings - American Journal of Cardiovascular Drugs, 14 (6), 451-462 - doi: 10.1007/s40256-014-0092-1
ME Hendriks, P Kundu, AC Boers, OA Bolarinwa, MJ te Pas, TM Akande, K Agbede, GB Gomez, Ken Redekop, C Schultsz & Siok Swan Tan (2014) - Step-by-step Guideline for disease-specific costing studies in low and middle income countries: a mixed methodology. - Global Health Action, 28 (7), 23573 - doi: 10.3402/gha.v7.23573
Amir Ansaripour, Carin Groot, Adri Steenhoek & Ken Redekop (2014) - The Drug Reimbursement Decision-Making System in Iran - Value in Health Regional Issues, 3, 174-181 - doi: 10.1016/j.vhri.2014.04.010
LT (Laura) Burgers, Ken Redekop & Hans Severens (2014) - Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease - Pharmacoeconomics (Print), 32 (7), 627-637 - doi: 10.1007/s40273-014-0155-9
Siok Swan Tan, A Geissler, L Serden, M Heurgren, Martin Ineveld, Ken Redekop & Leona Roijen (2014) - DRG systems in Europe: variations in cost accounting systems among 12 countries - European Journal of Public Health, 24 (6), 1023-1028 - doi: 10.1093 - [link]
Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2014) - Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? - Value in Health, 17, 245-253 - doi: 10.1016/j.jval.2013.12.009
Ken Redekop (2014) - Tools and techniques - statistics: comments on a cost-effectiveness study of TAVI for patients with inoperable aortic stenosis - EuroIntervention, 9 (10), 1241-1243 - doi: 10.4244/EIJV9I10A208
H Versteeg, Susanne Pedersen, MH Mastenbroek, Ken Redekop, JO Schwab, P Mabo & M Meine (2014) - Patient perspective on remote monitoring of cardiovascular implantable electronic devices: rationale and design of the REMOTE-CIED study - Netherlands Heart Journal, 22 (10), 423-428 - doi: 10.1007/s12471-014-0587-z
TI Verhoef, Ken Redekop, ML Bouvy, B Dorenbos, Z Karwar, RM van Schie, A de Boer & AH Maitland-van der Zee (2014) - Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users - British Journal of Clinical Pharmacology, 78 (2), 422-429 - doi: 10.1111/bcp.12346
LT (Laura) Burgers, Sjoerd Nauta, Jaap Deckers, Hans Severens & Ken Redekop (2014) - Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment? - International Journal of Cardiology, 176 (3), 980-987 - doi: 10.1016/j.ijcard.2014.08.134
JC Rejon-Parrilla, N Nuijten, Ken Redekop & JG (Jennifer G.) Gaultney (2014) - Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia - Health Policy and Technology, 3 (4), 314-324 - doi: 10.1016/j.hlpt.2014.08.004
TI Verhoef, Ken Redekop, AK Daly, RM van Schie, A de Boer & AH Maitland-van der Zee (2014) - Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon - British Journal of Clinical Pharmacology, 77 (4), 626-641 - doi: 10.1111/bcp.12220
Chantal Gils, Saskia Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154
Tim Kanters, I Hoogenboom-Plug, Maureen Molken, Ken Redekop, Ans Ploeg & Leona Roijen (2014) - Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease - Orphanet Journal of Rare Diseases, 9, 75 - doi: 10.1186/1750-1172-9-75
Annemieke Leunis, Ken Redekop, Carin Groot & Bob Löwenberg (2014) - Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study - European Journal of Haematology, 93 (3), 196-206 - doi: 10.1111/ejh.12324
Chantal Gils, Saskia Groot, Ken Redekop, M Koopman, CJA Punt & Carin Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6
Annemieke Leunis, Ken Redekop, Kees Montfort, Bob Löwenberg & Carin Groot (2013) - The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia - Pharmacoeconomics (Print) - doi: 10.1007/s40273-013-0058-1
JG (Jennifer G.) Gaultney, Margreet Franken, Siok Swan Tan, Ken Redekop, PC Huijgens, Pieter Sonneveld & Carin Groot (2013) - Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents - Journal of Clinical Pharmacy and Therapeutics, 38, 41-47 - doi: 10.1111/jcpt.12020
RR Soekhlal, LT (Laura) Burgers, Ken Redekop & Siok Swan Tan (2013) - Treatment costs for acute myocardial infarction in the Netherlands - Netherlands Heart Journal - doi: 10.1007/s12471-013-0386-y
TI Verhoef, G Ragia, A de Boer, R Barallon, G Kolovou, V Kolovou, S Konstantinides, S Le Cessie, E Maltezos, FJ van der Meer, Ken Redekop, M Remkes, FR Rosendaal, RM van Schie, A Tavridou, D Tziakis, M Wadelius, VG Manopoulos & AH Maitland-van der Zee (2013) - A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon - New England Journal of Medicine, 369 (24), 2304-2312 - doi: 10.1056/NEJMoa1311388
Ken Redekop & D Mladsi (2013) - The faces of personalized medicine: a framework for understanding its meaning and scope - Value in Health, 16 (6 Suppl), S4-S9 - doi: 10.1016/j.jval.2013.06.005
M Westwood, M Joore, JC Grutters, Ken Redekop, N Armstrong, K Lee, V Gloy, H Raatz, K Misso, Hans Severens & J Kleijnen (2013) - Contrast-enhanced ultrasound using SonoVue (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis - Health Technology Assessment, 17 (16), 1-243 - doi: 10.3310/hta17160
Linda Battes, Isabella Kardys, RJ (Rogier) Barendse, Ewout Steyerberg, M (Masoud) Amiri, Rene Eijkemans, Jaap Deckers, D Postmus, Hanneke Takkenberg, Ken Redekop & Eric Boersma (2013) - Microsimulation for Clinical Decision-Making in Individual Patients With Established Coronary Artery Disease - A Concept - Circulation Journal, 77 (3), 717-724 - doi: 10.1253/circj.CJ-11-1300
Tim Kanters, de Sonneville - Koedoot, Ken Redekop & Leona Roijen (2013) - Systematic review of available evidence on 11 high-priced inpatient orphan drugs - Orphanet Journal of Rare Diseases, 8 - doi: 10.1186/1750-1172-8-124
Tim Kanters, Iris Plug, Maureen Molken, Ken Redekop, Ans Ploeg & Leona Roijen (2013) - Cost-effectiveness of enzyme replacement therapy (ERT) with alglucosidase alfa in classic-infantile patients with Pompe disease - Value in Health, 16 (7), A384-A384 - doi: 10.1016/j.jval.2013.08.353
M Sunamura, Nienke Hoeve, Rita Emons, M Haverkamp, Ken Redekop, Marcel Geleijnse, Henk Stam, Eric Boersma & Ron Domburg (2013) - OPTImal CArdiac REhabilitation (OPTICARE) following Acute Coronary Syndromes: Rationale and design of a randomised, controlled trial to investigate the benefits of expanded educational and behavioural intervention programs - Netherlands Heart Journal, 21 (7-8), 324-330 - doi: 10.1007/s12471-013-0422-y
IE Hoefer, JW Sels, JW Jukema, S Bergheanu, E Biessen, E McClellan, M Daemen, P Doevendans, P de Groot, M Hillaert, S (Sebastiaan) Horsman, M Ilhan, J Kuiper, N Pijls, Ken Redekop, Peter Spek, Andrew Stubbs, E van de Veer, J Waltenberger, AJ van Zonneveld & G Pasterkamp (2013) - Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study - Clinical Research in Cardiology, 102, 847-856 - doi: 10.1007/s00392-013-0607-9
Margreet Franken, Chantal Gils, JG (Jennifer G.) Gaultney, GO Delwel, W Goettsch, PC Huijgens, Adri Steenhoek, CJA Punt, M Koopman, Ken Redekop & Carin Groot (2013) - Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands - European Journal of Cancer, 49, 8-16 - doi: 10.1016/j.ejca.2012.06.010
L Annemans, Ken Redekop & K Payne (2013) - Current Methodological Issues in the Economic Assessment of Personalized Medicine - Value in Health, 16, 20-26 - doi: 10.1016/j.jval.2013.06.008
CO Agyemang, Anton Kunst, R Bhopal, P Zaninotto, J Nazroo, N Unwin, I Valkengoed, Ken Redekop & VM Adao (2012) - A cross-national comparative study of metabolic syndrome among non-diabetic Dutch and English ethnic groups - European Journal of Public Health, 23 (3), 447-452 - doi: 10.1093/eurpub/cks041
JG (Jennifer G.) Gaultney, Ken Redekop, Pieter Sonneveld & Carin Groot (2012) - Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value - Expert Review of Anticancer Therapy, 12 (6), 839-854 - doi: 10.1586/era.12.42 - [link]
TI Verhoef, Ken Redekop, RMF van Schie, S Bayat, AK Daly, M Geitona, E Haschkebecher, DA Hughes, F Kamali, LA Levin, VG Manolopoulos, M Pirmohamed, U Siebert, JC Stingl, M Wadelius, A de Boer & AH Maitland-van der Zee (2012) - Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs - Pharmacogenomics, 13 (12), 1405-1417 - doi: 10.2217/pgs.12.124
Alejandra Mendez Romero, Joanne Verheij, Roy Dwarkasing, Yvette Seppenwoolde, Ken Redekop, Pieter Zondervan, Peter Nowak, JNM IJzermans, Peter Levendag, Ben Heijmen & Kees Verhoef (2012) - COMPARISON OF MACROSCOPIC PATHOLOGY MEASUREMENTS WITH MAGNETIC RESONANCE IMAGING AND ASSESSMENT OF MICROSCOPIC PATHOLOGY EXTENSION FOR COLORECTAL LIVER METASTASES - International Journal of Radiation Oncology Biology Physics, 82 (1), 159-166 - doi: 10.1016/j.ijrobp.2010.10.032
Siok Swan Tan, Leona Roijen, Martin Ineveld & Ken Redekop (2012) - Explaining length of stay variation of episodes of care in the Netherlands - European Journal of Health Economics (HEPAC), 14, 919-927 - doi: 10.1007/s10198-012-0436-1
TI Verhoef, Ken Redekop, MM Buikema, T Schalekamp, FJM van der Meer, S le Cessie, JAM Wessels, RMF van Schie, A den Boer, Martina Teichert, Loes Visser & AH Zee (2012) - Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users - Journal of Thrombosis and Haemostasis, 10 (4), 606-614 - doi: 10.1111/j.1538-7836.2012.04633.x
TI Verhoef, MJL Zuurhout, RMF van Schie, Ken Redekop, FJM van der Meer, S le Cessie, T Schalekamp, A de Boer & AH Maitland-van der Zee (2012) - The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon - British Journal of Clinical Pharmacology, 74 (6), 1068-1069 - doi: 10.1111/j.1365-2125.2012.04295.x
Chantal Gils, M Koopman, L (Linda) Mol, Ken Redekop, Carin Groot & CJA Punt (2012) - Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands - Acta Oncologica, 51, 57-64 - doi: 10.3109/0284186X.2011.633930
Anushka Omapersad, CJM de Groot, Ken Redekop, Renske Hoefman, Gerrit Koopmans, Vincent Jaddoe, Bert Hofman, EAP Steegers, MJ (Margo) Trappenburg, Johan Mackenbach & Marleen Foets (2012) - Differences in Quality of Antenatal Care Provided by Midwives to Low-Risk Pregnant Dutch Women in Different Ethnic Groups - Journal of Midwifery & Womens Health, 57 (5), 461-468 - doi: 10.1111/j.1542-2011.2012.00169.x
TI Verhoef, Ken Redekop, H Hegazy, A Boer & AH Maitland-van der Zee (2012) - Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users - Journal of Thrombosis and Haemostosis, 10 (12) - doi: 10.1111/jth.12007
M, Hendriks, L Brewster, F de Wit, OA Bolarinwa, AO Odusola, Ken Redekop, N Bindraban, BA Vollaard, S Alli, P Adenusi, K Agbede, T Akande, Johan Lange & C Schultsz (2011) - Cardiovascular disease prevention in rural Nigeria in the context of a community based health insurance scheme: QUality Improvement Cardiovascular care Kwara-I (QUICK-I) - BMC Public Health, 11 (186), 1-9 - doi: 10.1186/1471-2458-11-186
CO Agyemang, Anton Kunst, R Bhopal, P Zaninotto, J Nazroo, M Nicolaou, N Unwin, I Valkengoed, Ken Redekop & VM Adao (2011) - Dutch versus English advantage in the epidemic of central and generalised obesity is not shared by ethnic minority groups: comparative secondary analysis of cross-sectional data - International Journal of Obesity, 35, 1334-1346 - doi: 10.1038/ijo.2010.281
Renske Hoefman, Job Exel, S Looren-de Jong, Ken Redekop & Werner Brouwer (2011) - A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving - Quality of Life Research, 20, 875-887 - doi: 10.1007/s11136-010-9829-8
JG (Jennifer G.) Gaultney, E Sanhueza, JJ Janssen, Ken Redekop & Carin Groot (2011) - Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia - Pharmacogenomics, 12 (3), 411-421 - doi: 10.2217/pgs.10.187
CO Agyemang, Anton Kunst, R Bhopal, K Anujuo, P Zaninotto, J Nazroo, M Nicolaou, I Valkengoed, Ken Redekop & VM Adao (2011) - Diabetes Prevalence in Populations of South Asian Indian and African Origins - Epidemiology, 22 (4), 563-567 - doi: 10.1097/EDE.0b013e31821d1096
Anushka Omapersad, CJM de Groot, MA Bruijnzeels, Ken Redekop, Vincent Jaddoe, Bert Hofman, EAP Steegers, Johan Mackenbach & Marleen Foets (2011) - Ethnic differences in antenatal care use in a large multi-ethnic urban population in the Netherlands - Midwifery, 27 (1), 36-41 - doi: 10.1016/j.midw.2009.07.008
Anushka Omapersad, Gerrit Koopmans, Ken Redekop, CJM de Groot, Renske Hoefman, Vincent Jaddoe, Bert Hofman, EAP Steegers, Johan Mackenbach, MJ (Margo) Trappenburg & Marleen Foets (2011) - Explaining Ethnic Differences in Late Antenatal Care Entry by Predisposing, Enabling and Need Factors in the Netherlands. The Generation R Study - Maternal and Child Health Journal, 15 (6), 689-699 - doi: 10.1007/s10995-010-0619-2
JG (Jennifer G.) Gaultney, Ken Redekop, Pieter Sonneveld & Carin Groot (2011) - Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology - European Journal of Cancer, 47 (10), 1458-1467 - doi: 10.1016/j.ejca.2011.04.005
DS Cobden, LW (Louis Wilhelmus) Niessen, FFH Rutten & Ken Redekop (2010) - Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach - Patient Preference and Adherence, 4, 283-290
DS Cobden, LW (Louis Wilhelmus) Niessen, CE Barr, FFH Rutten & Ken Redekop (2010) - Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes - Value in Health, 13 (1), 138-147 - doi: 10.1111/j.1524-4733.2009.00587.x
TI Verhoef, Ken Redekop, J Darba, M Geitona, DA Hughes, U Siebert, A de Boer & AH Maitland-van der Zee (2010) - A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivates - Pharmacogenomics, 11 (7), 989-1002 - doi: 10.2217/pgs.10.74
T McLaughlin, M Buxton, T Mittendorf, Ken Redekop, L Mucha, J Darba, L Jonsson, L Lacey & C Leibman (2010) - Assessment op potential measures in models of progression in Alzheimer disease - Neurology, 75, 1256-1262 - doi: 10.1212/WNL.0b013e3181f6133d
FGW Cleveringa, PMJ Welsing, M van den Donk, KJ Gorter, LW (Louis Wilhelmus) Niessen, GEHM Rutten & Ken Redekop (2010) - Cost-Effectiveness of the Diabetes Care Protocol; a Multifaceted Computerized Decision Support Diabetes Management Intervention That Reduces Cardiovascular Risk - Diabetes Care, 33 (2), 258-263 - doi: 10.2337/dc09-1232
TI Verhoef, T Schalekamp, Ken Redekop, A Boer & AH Maitland-van der Zee (2010) - Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin - Expert review of pharmacoeconomics & outcomes research, 10 (4), 375-378 - doi: 10.1586/erp.10.42
Siok Swan Tan, FFH Rutten, Martin Ineveld, Ken Redekop & Leona Roijen (2009) - Comparing methodologies for the cost estimation of hospital services - European Journal of Health Economics (HEPAC), 10, 39-45 - doi: 10.1007/s10198-008-0101-x
Zahra Niazkhani, Heleen Sijs, Habibollah Pirnejad, Ken Redekop & Jos Aarts (2009) - Same system, different outcomes: Comparing the transitions from two paper-based systems to the same computerized physician order entry system - International Journal of Medical Informatics, 78, 170-181 - doi: 10.1016/j.ijmedinf.2008.06.012
RMF van Schie, M Wadelius, F Kamali, AK Daly, VG Manolopoulos, A Boer, R Barallon, TI Verhoef, J Kirchheiner, M Haschke-Becher, M Briz, FR Rosendaal, Ken Redekop, M Pirmohamed & AH Maitland - van der Zee (2009) - Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design - Pharmacoeconomics (Print), 10 (10), 1287-1295 - doi: 10.2217/pgs.09.125
Siok Swan Tan, Martin Ineveld, Ken Redekop & Leona Roijen (2009) - Comparing Methodologies for the Allocation of Overhead and Capital Costs to Hospital Services - Value in Health, 12 (4), 530-535 - doi: 10.1111/j.1524-4733.2008.00475.x
Ken Redekop, E Orlewska, P Maciejewski, FFH Rutten & LW (Louis Wilhelmus) Niessen (2008) - Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland - Pharmacoeconomics (Print), 26, 861-877
Siok Swan Tan, Ken Redekop & FFH Rutten (2008) - Costs and prices of single dental fillings in Europe: a micro-costing study - Health Economics, (17), 83-93 - doi: 10.1002/hec.1326
Elmar Delhaas, N (Nicoline) Beersen, Ken Redekop & NS (Niek) Klazinga (2008) - Long-term outcomes of continuous intrathecal baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study - Neuromodulation, (11), 227-236 - doi: 10.1111/j.1525-1403.2008.00170.x
CO Agyemang, R Bhopal & Ken Redekop (2007) - Does the pulse pressure in people of European, African and South Asian descent differ? A systematic review and meta-analysis of UK data - Journal of Human Hypertension, 21, 598-609 - doi: 10.1038/sj.jhh.1002191
HE (Bertien) Hart, Ken Redekop, HJG Bilo, B Meyboom- de Jong & M (Marc) Berg (2007) - Health related quality of life in patients with type I diabetes mellitus: generic & disease-specific measurement - Indian Journal of Medical Research, 125, 203-216
Jan-Jaap Visser, Marc Sambeek, Myriam Hunink, Ken Redekop, Lucas Dijk, Joke Hendriks & Joke Bosch (2006) - Cost analysis of endovascular repari and open surgery in patients with acute abdominal aortic aneurysms with one-year-follow-up - Radiology, 240, 681-689
Ken Redekop (2006) - Cost-effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database - Future Drugs, 6 (1), 41-48 - doi: 10.1586/14737167.6.1.41
Jan-Jaap Visser, MRHM Sambeek, Myriam Hunink, Ken Redekop, Lucas Dijk, Joke Hendriks & Joke Bosch (2006) - Acute abdominal aortic aneurysms: cost analysis of endovascular repair and open surgery in hemodynamically stable patients with 1-year follow-up - Radiology, 240 (3), 681-689 - doi: 10.1148/radiol.2403051005
Werner Brouwer, Job Exel, B van Gorp & Ken Redekop (2006) - The CarerQol instrument: A new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations - Quality of Life Research, 15, 1005-1021 - doi: 10.1007/s11136-005-5994-6
N (Nicoline) Beersen, Ken Redekop, JHB (J.H. Bart) de Bruijn, PJ Theuvenet, M (Marc) Berg & NS (Niek) Klazinga (2005) - Quality based social insurance coverage and payment of the application of a high cost medical therapy: the case of spinal cord stimulation for chronic non-oncologic pain in The Netherlands - Health Policy, 71 (1), 107-115 - doi: 10.1016/j.healthpol.2004.08.002
CO Agyemang, Ken Redekop, E Owusu-Dabo & MA Bruijnzeels (2005) - Blood pressure patterns in rural, semi-urban and urban children in the Ashanti region of Ghana, West Africa - BMC Public Health, 5 - doi: 10.1186/1471-2458-5-114
CO Agyemang, R Bhopal, MA Bruijnzeels & Ken Redekop (2005) - Does the white-coat effect in people of African and South Asian descent differ from that in White people of European origin? A systematic review and meta-analysis - Blood Pressure Monitoring, 10 (5), 243-248 - doi: 10.1097/01.mbp.0000172712.89910.e4
CO Agyemang, R Bhopal, MA Bruijnzeels & Ken Redekop (2005) - Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis - Journal of Hypertension, 23 (5), 913-920
HE (Bertien) Hart, Ken Redekop, HJG Bilo, M (Marc) Berg & BM Jong (2005) - Change in perceived health and functioning over time in patients with type I diabetes mellitus - Quality of Life Research, 14, 1-10 - doi: 10.1007/s11136-004-0782-2
MJMH Lombarts, NS (Niek) Klazinga & Ken Redekop (2005) - Measuring the perceived impact of facilitation on implementing recommendations from external assessment: lessons from the Dutch visitatie programme for medical specialists - Journal of Evaluation in Clinical Practice, 11 (6), 587-597 - doi: 10.1111/j.1365-2753.2005.00595.x
J Raad & Ken Redekop (2005) - Analysis of health factors as predictors for the funcitoning of military personnel: study of the factors that predict fitness for duty and medical costs of soldiers of the Royal Netherlands Army - Military Medicine, 170, 14-20
HE (Bertien) Hart, Ken Redekop, M (Marc) Berg, HJG Bilo & B Meyboom- de Jong (2005) - Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients - Journal of Clinical Epidemiology, 58, 1158-1164 - doi: 10.1016/j.jclinepi.2005.02.021
MM Ortegon, Ken Redekop & LW (Louis Wilhelmus) Niessen (2004) - Cost-effectiveness of prevention and treatment of the diabetic foot - Diabetes Care, 27, 901-907 - doi: 10.2337/diacare.27.4.901
Ken Redekop, Elly Stolk, E Kok, K Lovas, Z Kalo & Jan Busschbach (2004) - Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments - Diabetes & Metabolism, 30, 549-556
N (Nicoline) Beersen, JHB (J.H. Bart) de Bruijn, MA (Monique) Dekkers, P ten Have, G Hekster, Ken Redekop, GHJJ Spincemaille, PJ Theuvenet, M (Marc) Berg & NS (Niek) Klazinga (2004) - Developing a national continuous quality improvement system for neuromodulation treatment in the Netherlands - Journal of Quality and Safety. Joint Commission Journal on Quality Improvement, 30, 310-321
Ken Redekop (2004) - Does improved glycaemic control lead to a better short-term quality of life in diabetes mellitus type 2? - Postgraduate Medical Journal, 50, 194-194
Ken Redekop, J Mcdonnell, P (Paul) Verboom, K Lovas & Z Kalo (2003) - The cost effecitveness of Apligraf treatment of diabetic foot ulcers - Pharmacoeconomics (Print), 21 (16), 1171-1183 - doi: 10.2165/00019053-200321160-00003
HE (Bertien) Hart, HJG Bilo, Ken Redekop & RP (Ronald) Stolk (2003) - Quality of life of patients with type I diabetes mellitus - Quality of Life Research, 12, 1089-1097
Ken Redekop, Marc Koopmanschap, Elly Stolk, FFH Rutten, BHR Wolffenbuttel & LW (Louis Wilhelmus) Niessen (2002) - Health related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes - Diabetes Care, 25 (3), 458-463 - doi: 10.2337/diacare.25.3.458
Ken Redekop, Marc Koopmanschap, FFH Rutten, BHR Wolffenbuttel, Elly Stolk & LW (Louis Wilhelmus) Niessen (2002) - Resource consumption and costs in Dutch patients with Type II diabetes mellitus. Results from 29 general practices - Diabetic Medicine, 19, 246-253 - doi: 10.1046/j.1464-5491.2002.00654.x
Rianne Oostenbrink, JB (Jan) Oostenbrink, KGM (Karel) Moons, G (Gerarda) Derksen-Lubsen, Marie-louise Bot, DE Grobbee, Ken Redekop & Henriette Moll (2002) - Cost-utility analysis of patient care in children with meningeal signs - International Journal of Technology Assessment in Health Care, 18 (3), 485-496
J Mcdonnell, Ken Redekop, N van der Roer, ES Goes, A Ruitenberg, Jan Busschbach, Monique Breteler & FFH Rutten (2001) - The costs of treatment of Alzheiemers's disease in The Netherlands. A regression-based simulation model. - Pharmacoeconomics (Print), 19 (4), 379-390
A Ruitenberg, S (Sandra) Kalmijn, Maria Ridder, Ken Redekop, F (Frans) van Harskamp & A Hof (2001) - Prognosis of Alzheimer's Disease: The Rotterdam Study - Neuroepidemiology, 20 (3), 188-195 - doi: 10.1159/000054786
Leona Roijen, P (Paul) Verboom, Ken Redekop, CR Touw & FFH Rutten (2001) - The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis - Pharmacoeconomics (Print), 19, 599-608
EM Koomen, BA Hutten, JC (Johannes) Kelder, Ken Redekop, Kedir Adal & JH Kingma (2001) - Morbidity and mortality in patients waiting for coronary artery bypass surgery - European Journal of Cardio-thoracic Surgery, 19 (3), 260-265
HE (Bertien) Hart, Ken Redekop, HJG Bilo, JH (Jan Hendrik) Assink & AF (Anton) Casparie (2001) - Quality of life in patients with type I diabetes mellitus - Netherlands Journal of Medicine, 58, 2-2
Rick Jansen, Ken Redekop & FFH Rutten (2001) - Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.O.N. study, Lamisil versus Itraconazole in Onychomycosis - Pharmacoeconomics (Print), 19 (4), 401-410

M Westwood, H Raatz, K Misso, LT (Laura) Burgers, Ken Redekop, SK (Stefan) Lhachimi, N Armstrong & J Kleijnen (2013) - Systematic review of the accuracy of dual-source cardiac CT for detection of arterial stenosis in difficult to image patient groups - Radiology, 267 (2), 387-395 - doi: 10.1148/radiol.13121136/-/DC1
CO Agyemang, Anton Kunst, R Bhopal, P Zaninotto, N Unwin, J Nazroo, M Nicolaou, Ken Redekop & VM Adao (2011) - Hypertensie in Nederlandse en Engelse etnische minderheidsgroepen - Nederlands Tijdschrift voor Geneeskunde, A3318 (155), 1-9
Martin Ineveld, Peter Dohmen & Ken Redekop (2006) - De startende marktwerking in de gezondheidszorg - Economisch-Statistische Berichten, 91 (4494), 470-473
J Raad & Ken Redekop (2004) - A comparison between two systems for pre-employment medical assessment in the Royal Netherlands Army by a randomized, controlled study - Military Medicine, 169, 437-443
Ken Redekop & Marc Koopmanschap (2004) - Economische aspecten van polyfarmacie bij diabetes - CBO, 8-22

KA Phillips, K Payne & Ken Redekop (2016) - Personalized Medicine: Economic Evaluation and Evidence - World Scientific
RMF van Schie, TI Verhoef, AH Maitland-van der Zee, A de Boer, FJM van der Meer, Ken Redekop & R Thariani (2012) - Future of Pharmacogenetics in Cardiovascular Diseases - doi: 10.5772/2218 - InTech
Siok Swan Tan, L Serden, A Geissler, Martin Ineveld, Ken Redekop, M Heurgren & Leona Roijen (2011) - DRGs and cost accounting: Which is driving which? - Open University Press
Siok Swan Tan, Martin Ineveld, Ken Redekop & Leona Roijen (2011) - The Netherlands: The Diagnose Behandeling Combinaties - Open University Press

Ken Redekop (2017) - Personalised medicine to improve cardiovascular health - The Hippocrates Press

DRJ Singer, Ken Redekop & B Cheung (2020) - Trusted writing in social media: FPM international awards for medical writing in social media - Postgraduate Medical Journal, 96 (1134), 183-183 - doi: 10.1136/postgradmedj-2020-137620

HE (Bertien) Hart, Ken Redekop, HJG Bilo, Jan Busschbach & AF (Anton) Casparie (2001) - Quality of life over time in a cohort of patients with type 1 diabetes mellitus measured with the Euroqol and the SF-36

Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma - Erasmus Universiteit Rotterdam - GE-iMTA

M Westwood, Maiwenn Al, LT (Laura) Burgers, Ken Redekop, SK (Stefan) Lhachimi, N Armstrong, H Raatz, K Misso, Hans Severens & J Kleijnen (2013) - A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD. - doi: 10.3310/hta17090 - Health Technology Assessment
Isabelle Fabbricotti, M Oud, Ken Redekop & Robbert Huijsman (2011) - De meerwaarde van HKZ-certificering voor GGZ-instelling - Erasmus Universiteit Rotterdam (EUR)
N van der Roer, Jan Busschbach, ES Goes, Leona Roijen & Ken Redekop (2001) - Kosten van de ziekte van Alzheimer; een studie naar de belangrijkste kostenposten voor patiënten met de ziekte van Alzheimer in Nederland en in Frankrijk

Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran